MDPI and ACS Style
Kim, J.; Park, K.E.; Jeong, Y.-S.; Kim, Y.; Park, H.; Nam, J.-H.; Jung, K.; Son, W.S.; Jung, H.S.; Lee, J.-H.;
et al. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers 2020, 12, 1575.
https://doi.org/10.3390/cancers12061575
AMA Style
Kim J, Park KE, Jeong Y-S, Kim Y, Park H, Nam J-H, Jung K, Son WS, Jung HS, Lee J-H,
et al. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers. 2020; 12(6):1575.
https://doi.org/10.3390/cancers12061575
Chicago/Turabian Style
Kim, Jooseok, Kyung Eui Park, Yoo-Seong Jeong, YeongMun Kim, Hayeon Park, Ji-Hye Nam, Kyungsoo Jung, Woo Sung Son, Hun Soon Jung, Jong-Hwa Lee,
and et al. 2020. "Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer" Cancers 12, no. 6: 1575.
https://doi.org/10.3390/cancers12061575